Rimegepant is an orally disintegrating tablet that belongs to the calcitonin gene-related peptide (CGRP) receptor antagonist class.

1、 Drug name

Common name: Rimegepant

Product Name: NURTECODT (Oral Disintegrating Tablets)

2、 Indications

Used for acute treatment of migraine with or without premonitory symptoms in adults.

Usage restrictions: Not applicable for preventive treatment of migraine.

3、 Specifications and characteristics

75mg orally disintegrating tablets.

4、 Main components

Active ingredient: Rimazepam sulfate (equivalent to 75 milligrams of Rimazepam free base)

5、 Usage and dosage

The recommended dosage is 75mg orally, taken as needed.

The maximum dose within 24 hours is 75 milligrams.

The safety of treating migraine more than 15 times within 30 days has not been determined.

6、 Dose adjustment

Mild or moderate liver dysfunction patients do not require dose adjustment, while severe liver dysfunction (Child Pugh C grade) patients are contraindicated.

Patients with any degree of renal insufficiency do not need to adjust the dosage, but it is contraindicated for end-stage renal disease (CLcr<15mL/min) or dialysis patients.

7、 Medication precautions

Medication timing: There are no restrictions on taking medication before or after meals in clinical studies.

Omission treatment: As an on-demand treatment medication, there is no need to supplement.

Vomiting treatment: The instructions are not clearly stated, it is recommended to consult a doctor.

8、 Medication for special populations

Pregnant women: Without sufficient data, animal studies have shown that high doses have developmental toxicity.

Breastfeeding period: It is unknown whether it has entered breast milk, and the pros and cons need to be weighed.

Children: Safety and efficacy have not been established.

Elderly: There is no significant difference in pharmacokinetics.

9、 Adverse reactions

The most common adverse reaction is nausea (with an incidence rate of 2%).

The incidence of hypersensitivity reactions (including difficulty breathing and rash) is less than 1% and may occur several days later.

10、 Contraindications

Patients with a history of allergies to remifentanil, NURTECODT, or any of the ingredients are contraindicated.

11、 Drug interactions

Strong CYP3A4 inhibitors: Do not use in combination.

Intermediate acting CYP3A4 inhibitor: Avoid re administration within 48 hours when used in combination.

Strong or moderate CYP3A inducers: Do not use in combination.

P-gp or BCRP inhibitors: co administration is prohibited.

12、 Storage method

Store at room temperature (20 ° C-25 ° C), allowing fluctuations within the range of 15 ° C-30 ° C.

It should be stored in the original aluminum-plastic blister packaging and taken immediately after removal.

Rimegepantinformation